Analysts Set Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Price Target at $66.00

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have earned a consensus rating of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $66.00.

Several equities research analysts recently issued reports on AMPH shares. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, May 22nd. Piper Sandler reiterated an “overweight” rating and set a $71.00 target price on shares of Amphastar Pharmaceuticals in a research note on Thursday, June 27th. Finally, StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 13th.

Insider Transactions at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 3,596 shares of the business’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total value of $147,184.28. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $3,851,635.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO William J. Peters sold 3,596 shares of the firm’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $40.93, for a total transaction of $147,184.28. Following the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $3,851,635.79. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $41.40, for a total transaction of $124,200.00. Following the completion of the sale, the director now directly owns 78,409 shares of the company’s stock, valued at approximately $3,246,132.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,596 shares of company stock worth $313,544. Company insiders own 27.10% of the company’s stock.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC raised its position in Amphastar Pharmaceuticals by 0.8% during the fourth quarter. Exchange Traded Concepts LLC now owns 21,440 shares of the company’s stock valued at $1,326,000 after purchasing an additional 169 shares in the last quarter. Quadrant Capital Group LLC grew its holdings in shares of Amphastar Pharmaceuticals by 27.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after purchasing an additional 223 shares during the last quarter. Bridge City Capital LLC increased its position in Amphastar Pharmaceuticals by 0.8% during the 1st quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock worth $1,527,000 after purchasing an additional 275 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its stake in Amphastar Pharmaceuticals by 2.7% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 14,923 shares of the company’s stock valued at $655,000 after purchasing an additional 399 shares during the last quarter. Finally, Texas Permanent School Fund Corp lifted its stake in Amphastar Pharmaceuticals by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 32,704 shares of the company’s stock valued at $1,436,000 after purchasing an additional 424 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Up 2.6 %

Shares of Amphastar Pharmaceuticals stock opened at $38.56 on Thursday. The stock has a market cap of $1.89 billion, a P/E ratio of 13.34, a P/E/G ratio of 0.82 and a beta of 0.80. The company has a quick ratio of 1.72, a current ratio of 2.18 and a debt-to-equity ratio of 0.88. Amphastar Pharmaceuticals has a 12-month low of $37.30 and a 12-month high of $67.66. The business’s 50 day moving average is $41.47 and its 200-day moving average is $47.42.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.20. Amphastar Pharmaceuticals had a net margin of 22.88% and a return on equity of 29.17%. The firm had revenue of $171.84 million for the quarter, compared to analyst estimates of $171.13 million. Equities research analysts predict that Amphastar Pharmaceuticals will post 3.6 earnings per share for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.